Health Canada approves Quviviq for the management of adult patients with insomnia.- Idorsia Ltd.
Idorsia Ltd announced that Health Canada has granted marketing authorization for Quviviq (daridorexant) for the management of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, on April 28, 2023.
Insomnia is one of the most prevalent sleep disorders in Canada, affecting over 2.2 million working age Canadians with an estimated annual GDP lost in Canada due to reduced productivity associated with chronic insomnia of US$ 19.6 billion, and impacting both physical and mental health.
Quviviq is a dual orexin receptor antagonist (DORA) acting on both orexin 1 and orexin 2 receptors equipotently. Rather than inducing sleep through broad inhibition of brain activity (sedation), Quviviq blocks only the activation of orexin receptors which promote wakefulness. Consequently, for patients with insomnia, Quviviq decreases the over-active wake drive, allowing sleep to occur, without altering the proportion of sleep stages.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins